EU com­mit­tee con­firms neg­a­tive opin­ion for Amy­lyx ALS drug, re­ject­ing com­pa­ny ap­peal

The Eu­ro­pean Med­i­cines Agency re­ject­ed on Fri­day an ap­peal from Amy­lyx Phar­ma­ceu­ti­cals to re­con­sid­er a neg­a­tive re­view opin­ion for its ALS drug Re­lyvrio, fur­ther dim­ming …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER